Recruiting

Observational Study

Sponsor:

PersImmune, Inc

Code:

NCT03072498

Conditions

Myelodysplastic Syndromes(MDS)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

The purpose of this study is to collect information and bone marrow, blood, saliva, cheek cells and skin to be used in the laboratory to assist the sponsor in identifying a new way of treating MDS.

Conditions

Myelodysplastic Syndromes(MDS)

Study ID

NCT03072498

Start date

Apr 6, 2017

Status verified date

Mar, 2019

Completion date

Mar 5, 2021

Anticipated

Primary completion date

Dec 5, 2020

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Patients must meet the following initial inclusion criteria:

  • Diagnosis or suspected diagnosis of MDS or CCUS
  • Age 18 or older

Patient exclusion criteria:

  • Currently receiving or within 3 months has received hypomethylating agent(s), lenalidomide, cytotoxic agents, or within the previous 4 weeks corticosteroids > 5 mg prednisone daily or any other immunosuppressants
  • Previous allogenic transplant
  • Inability to provide consent
  • Prisoners

Study Design

Enrollment

24 participants

Anticipated

Interventions and Outcome Measures

Primary outcome measure

  • Genomics of patients with MDS [ Time Frame: 2 years ]

Central Contacts and Locations

Central contacts

Rafael Bejar, MD

858-822-5485rabejar@ucsd.edu

Tiffany Tanaka, MD

858-534-8575tntanaka@ucsd.edu

Locations

University of California, Irvine

Recruiting

Irvine, California, United States, 92868

Contacts

Chao Family Comprehensive Cancer Center

877-827-8839ucstudy@uci.edu

Jessica Limson

7145096233rlimson@uci.edu

Principal Investigator:

Deepa Jeyakumar, M.D.

University of California San Diego

Recruiting

La Jolla, California, United States, 92093

Contacts

Colin McCarthy

858-534-8127c4mccarthy@ucsd.edu

Kimberly Aguilar

858-534-5201k1aguilar@ucsd.edu

Principal Investigator:

Rafael Bejar, M.D., Ph.D.

More Information

Sponsor

PersImmune, Inc

Last update posted

Mar 26, 2019

Last verified

Mar, 2019

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by PersImmune, Inc on 2019-03-26.